Given that SLC7A11 is upregulated in metastatic HNSCC compared to primary tumors, and that disulfidptosis selectively targets cells with high SLC7A11 expression, it can be theorized that disulfidptosis holds a specific advantage over ferroptosis in selectively targeting metastatic or recurrent lesions—particularly in the context of targeted therapy for such lesions [112]. The gene discussed is SLC7A11; the disease is head and neck squamous cell carcinoma.